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We reviewed data pertaining to the massive wave of Lassa 
fever cases that occurred in Nigeria in 2018. No new virus 
strains were detected, but in 2018, the outbreak response 
was intensified, additional diagnostic support was available, 
and surveillance sensitivity increased. These factors prob-
ably contributed to the high case count.
A massive wave of laboratory-confirmed cases of Lassa fever occurred in Nigeria in 2018. Whether this high 
case count was caused by a new virus variant, increased 
seasonal incidence, improved case recognition, availability 
of laboratory diagnostics and therapy, or a combination of 
these factors is unknown. We set out to determine the fac-
tors that contributed to this outbreak using data available 
through the Nigerian Disease Surveillance System.
Lassa fever is endemic in Nigeria and peaks during 
the first 12 weeks of the year (January–March; Figure) 
(https://ncdc.gov.ng/themes/common/files/sitreps/b7cd-
08c8047e52ceabb09e5318a3b0a7.pdf). A total of 107 
laboratory-confirmed cases were reported during the 
first 12 weeks of 2017 and 394 during the same period 
in 2018. Among confirmed and probable cases, 50 deaths 
were reported during the peak season in 2017 and 104 in 
2018. In the neighboring states of Edo and Ondo, 45.0% 
of confirmed cases occurred in 2017 and 66.0% in 2018. 
These states have access to the long-established and larg-
est Lassa fever treatment center that has Lassa virus di-
agnostic capabilities in Nigeria. Although Edo and Ondo 
comprise only 4.6% of Nigeria’s population, the popula-
tion in these states accounted for 74.6% of the increase in 
confirmed cases during the 2017 and 2018 peak seasons. 
Another area with a strong increase in case numbers in 
2018 was the nonadjacent Ebonyi State, where another 
laboratory was outfitted to conduct Lassa virus diagnos-
tics by early 2018.
Evidence from sequencing studies yielded no indica-
tion that viruses circulating in 2018 were different from 
those found in previous years (1). Phylogenetic data sug-
gest multiple zoonotic infections instead of extensive per-
son-to-person transmission.
The increased case numbers in Edo, Ondo, and Eb-
onyi could not be accounted for by gross population 
changes; these states are distant from the refugee emer-
gency in northeastern Nigeria (http://reporting.unhcr.org/
node/21275). Studies on climatic and other environmental 
circumstances (e.g., new agricultural practices or larger 
harvests) that could have potentially contributed to changes 
in the way and frequency humans come into contact with 
the Lassa virus reservoir, Mastomys natalensis mice, have 
not been established. Also, data on rodent abundance are 
not available.
However, in 2018, many changes occurred in Ni-
geria regarding Lassa virus surveillance and treatment. 
Instead of only 1 Lassa virus laboratory for Edo and 
Ondo and 1 in Lagos, 2 additional laboratories (in Eb-
onyi and Abuja) started providing diagnostic services 
in early 2018. Sample transport logistics had improved, 
and patients’ samples were transported and tested with-
out charge. Considering that laboratory confirmation is 
a prerequisite for counting cases, laboratory capacity 
building directly affects surveillance case numbers. By 
early 2018, Lassa fever surveillance had been strength-
ened by the formulation of standard operating proce-
dures, and rapid response teams provided capacity build-
ing and support to affected states 4 weeks earlier than 
they did in 2017. Clinical cases of Lassa fever need to 
be treated in isolation facilities, and by 2018, additional 
treatment centers had been assessed and were being sup-
ported by the federal government. At this time, ribavirin 
was also available to patients without charge, and the 
media actively advertised this message, encouraging pa-
tients to seek medical treatment. In addition, Lassa fever 1These first authors contributed equally to this article.
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received strong media attention in early January 2018 
because of an incident in a healthcare facility where 3 of 
4 infected healthcare workers died.
Surveillance data are incomplete for 2018, but higher 
surveillance sensitivity is visible in the available data from 
the peak 2017 and 2018 seasons. The percentage of sus-
pected Lassa fever cases testing positive decreased from 
31.0% in 2017 to 21.6% in 2018 (30.2% decrease). Nose-
bleed, an indicator of disease severity in nonfatal confirmed 
cases, was noted on 10.8% of case report forms for surviv-
ing patients in 2017, but this frequency declined to 2.6% in 
2018 (75.9% decrease), and the case-fatality ratio among 
confirmed and probable cases declined from 43.9% in 2017 
to 25.8% in 2018 (41.2% decrease). Disease severity and 
case-fatality ratios are also influenced by the timeliness 
of patients seeking treatment and treatment availability. 
The decrease in the 3 aforementioned factors (percentage 
of Lassa virus–positive cases, percentage of nonfatal con-
firmed cases with nosebleeds, and case-fatality ratio) re-
flects lowering of the surveillance threshold to detect cases. 
More patients with comparatively mild disease probably 
sought treatment because of the increased Lassa fever pub-
licity and communication about available therapy; more-
over, additional suspected cases were probably detected in 
the community through enhanced contact tracing and ac-
tive case finding.
In conclusion, we cannot exclude that early 2018 
represents a particularly active Lassa fever season in Ni-
geria, especially in Edo, Ondo, and Ebonyi. However, 
no available evidence indicates that higher case numbers 
could be attributed to new virus strains. The addition of 
new laboratories with growing surveillance capacities, an 
overall intensified response, and increasing surveillance 
sensitivity are likely major drivers of the high number 
of Lassa fever cases reported in early 2018. The week-
ly case numbers reported in early 2019 slightly surpass 
those from 2018 (https://ncdc.gov.ng/themes/common/
files/sitreps/b94e459c79a59ca9d667a55539cda5db.pdf). 
Improved identification of Lassa fever cases in Nigeria 
provides the basis for epidemiologic studies of disease 
and effective disease control. Also, each identified case 
treated in isolation centers reduces the likelihood of per-
son-to-person transmission.
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